SIMIONI, Carolina
 Distribuzione geografica
Continente #
NA - Nord America 2.697
EU - Europa 1.372
AS - Asia 655
SA - Sud America 82
AF - Africa 8
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.820
Nazione #
US - Stati Uniti d'America 2.669
PL - Polonia 500
IT - Italia 368
CN - Cina 262
SG - Singapore 191
DE - Germania 142
UA - Ucraina 112
TR - Turchia 79
GB - Regno Unito 73
BR - Brasile 72
SE - Svezia 48
ID - Indonesia 47
FI - Finlandia 44
CA - Canada 26
VN - Vietnam 26
BE - Belgio 16
FR - Francia 14
RU - Federazione Russa 13
NL - Olanda 11
HK - Hong Kong 9
AT - Austria 6
CZ - Repubblica Ceca 5
LT - Lituania 5
PK - Pakistan 5
AR - Argentina 4
AU - Australia 4
IN - India 4
JP - Giappone 4
NP - Nepal 4
TW - Taiwan 4
BD - Bangladesh 3
DZ - Algeria 3
ES - Italia 3
HU - Ungheria 3
IQ - Iraq 3
IR - Iran 3
CH - Svizzera 2
EC - Ecuador 2
EU - Europa 2
IE - Irlanda 2
IL - Israele 2
JO - Giordania 2
KE - Kenya 2
MX - Messico 2
RO - Romania 2
SA - Arabia Saudita 2
AL - Albania 1
BH - Bahrain 1
CG - Congo 1
CL - Cile 1
CO - Colombia 1
EG - Egitto 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
OM - Oman 1
PT - Portogallo 1
PY - Paraguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 4.820
Città #
Warsaw 500
Fairfield 383
Woodbridge 280
Houston 214
Ashburn 175
Chandler 171
Ferrara 162
Santa Clara 160
Ann Arbor 156
Seattle 152
Cambridge 144
Singapore 142
Wilmington 139
Jacksonville 127
Izmir 55
Princeton 49
Milan 48
Jakarta 46
Nanjing 46
Beijing 42
Shanghai 35
San Diego 29
Boardman 25
Dearborn 24
Dong Ket 24
Los Angeles 24
Munich 21
Helsinki 19
Nanchang 18
Shenyang 18
Brussels 16
Bologna 13
Frankfurt am Main 13
Falkenstein 12
Montréal 12
Changsha 11
New York 11
Auburn Hills 10
Hebei 8
Jinan 8
Kunming 8
London 8
Bremen 7
Redwood City 7
São Paulo 7
Toronto 7
Addison 6
Falls Church 6
Guangzhou 6
Norwalk 6
Nuremberg 6
Redmond 6
Rome 6
Tianjin 6
Des Moines 5
Hefei 5
Imola 5
Ottawa 5
Zhengzhou 5
Augusta 4
Cagliari 4
Forlì 4
Hangzhou 4
Hong Kong 4
Mcallen 4
Mountain View 4
Taipei 4
Washington 4
Albuquerque 3
Belo Horizonte 3
Budapest 3
Catania 3
Ferrara di Monte Baldo 3
Florence 3
Lanzhou 3
Lappeenranta 3
Naples 3
Ningbo 3
Palermo 3
Parma 3
Phoenix 3
Rio de Janeiro 3
San Mateo 3
Tappahannock 3
Amman 2
Ancona 2
Baghdad 2
Bassano Del Grappa 2
Campo Grande 2
Castel San Pietro Terme 2
Civitanova Marche 2
Clifton 2
Cologno Monzese 2
Council Bluffs 2
Focsani 2
Genoa 2
Hanoi 2
Jeddah 2
Jiaxing 2
Kilburn 2
Totale 3.775
Nome #
Targeting mTOR in Acute Lymphoblastic Leukemia 215
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines 203
PHARMACOLOGICAL CHARACTERIZATION OF THE SIGNAL TRANSDUCTION PATHWAYS MODULATED BY A3 RECEPTORS IN CANCER CELLS: POSSIBLE TARGETS FOR THERAPEUTIC INTERVENTION. 192
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update 181
The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells 175
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia 165
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging 158
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 156
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia 155
miRNAs as Influencers of Cell-Cell Communication in Tumor Microenvironment 155
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia 154
Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments 141
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. 137
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 136
Adenosine receptors and cancer 134
Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors 121
Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells 114
null 112
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 111
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 107
L'ipossia inibisce l'apoptosi indotta da paclitaxel mediante fosforilazione di BAD dipendente dall'adenosina nelle cellule di glioblastoma. 99
Pharmacological characterization of adenosine receptors in bovine chondrocytes. 99
null 95
New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: recent advances 91
Cytotoxic drugs regulate VEGF and IL-8 expression in human melanoma cells by A2A and A3 adenosine receptors. 88
null 86
null 86
null 84
PI3K/Akt/mTOR Pathway in Acute Lymphoblastic Leukemia Targeted Therapies 84
SARS-CoV-2 nucleocapsid-protein and ultrastructural modifications in small bowel of a four week negative COVID-19 patient 79
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells 77
Binding thermodynamics at the human A2B adenosine receptor. 74
A3 ADENOSINE RECEPTORS MODULATE HYPOXIA-INDUCIBLE FACTOR-1ALPHA EXPRESSION IN HUMAN CANCER CELLS 71
Cell cycle block by p53 acrivation reduces SARS-COV-2 release in infected alveolar basal epithelial A549-hACE2 cells 68
VEGF and IL-8 regulation by cytotoxic drugs in human melanoma cells: molecular mechanism modulated by A2B and A3 adenosine receptors 67
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation. 56
The novel Akt inhibitor MK-2206, is cytotoxic in T-cell acute lymphoblastic leukemia: Therapeutic implications 54
Legislation to limit the environmental plastic and microplastic pollution and their influence on human exposure 51
The mTOR inhibitor, RAD001, displays higher cytotoxicity in leukemias with hyperactivated PI3K/AKT/mTOR pathway 49
Optical tissue clearing associated with 3D imaging: application in preclinical and clinical studies 49
Therapeutic potential of the novel mTOR inhibitor Torin-2 to overcome AKT reactivation in B-precursor acute lymphoblastic leukemia (B-pre ALL). 46
The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies 43
Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives 42
Relevance of VEGF and CD147 in different SARS-CoV-2 positive digestive tracts characterized by thrombotic damage 42
Micrornas patterns as potential tools for diagnostic and prognostic follow‐up in cancer survivorship 40
A2B AND A3 ADENOSINE RECEPTORS MODULATE VASCULAR ENDOTHELIAL GROWTH FACTOR AND INTERLEUKIN-8 EXPRESSION IN HUMAN MELANOMA CELLS TREATED WITH ETOPOSIDE AND DOXORUBICIN. 38
The role of extracellular vesicles as shuttles of RNA and their clinical significance as biomarkers in hepatocellular carcinoma 36
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. 31
Microalgae as a Nutraceutical Tool to Antagonize the Impairment of Redox Status Induced by SNPs: Implications on Insulin Resistance 30
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 27
Effects of SARS-COV-2 on molecules involved in vascularization and autophagy in placenta tissues 23
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy 22
Regulation of Second Messenger Systems and Intracellular Pathways. 20
Totale 4.969
Categoria #
all - tutte 25.324
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 979
Totale 26.303


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020411 0 0 0 0 0 0 0 109 106 92 51 53
2020/20211.026 60 78 54 79 132 106 67 98 46 169 69 68
2021/2022434 20 35 21 4 36 36 13 35 15 47 55 117
2022/2023467 55 36 26 42 60 49 42 31 45 30 37 14
2023/2024299 28 35 22 6 15 29 19 22 5 10 15 93
2024/2025720 39 47 115 74 180 125 93 47 0 0 0 0
Totale 4.969